Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer-BioNTech agree to supply WHO co-led COVID-19 vaccine scheme -sources

01/21/2021 | 02:43pm EST

LONDON/FRANKFURT, Jan 21 (Reuters) - Pfizer and BioNTech have agreed to supply their COVID-19 vaccine to the World Health Organization co-led COVAX vaccine access scheme, two sources familiar with the deal said, the latest in a series of shots to be included in the project aimed at lower-income countries.

The deal is expected to be announced on Friday, according to the sources, who declined to be named due to the confidentiality of the agreement.

Details on the size of the deal or the price per dose COVAX would pay were not immediately clear, but the sources said the allotment would likely be relatively small. One source said the reason for the limited volume was that the doses were primarily meant for healthcare workers in the countries that COVAX serves.

BioNTech declined to comment while Pfizer did not respond to requests for comment. Spokespeople for the WHO and the GAVI vaccine alliance, which co-leads the COVAX scheme, also declined to comment.

Senior WHO adviser Bruce Aylward said on Monday the COVAX scheme was in "very detailed discussions" with Pfizer, which has already committed hundreds of millions of doses this year to several wealthy nations, and expected to be able to include the vaccine in COVAX "very soon".

The COVAX scheme is set to start distributing COVID-19 vaccines to poor and middle income countries in February.

Ukraine said earlier on Thursday that its first delievery of COVID-19 vaccine under the COVAX scheme could arrive in the first half on February - with 210,000 doses of either the Moderna, Pfizer or AstraZeneca vaccines.

COVAX has said it hopes to deliver more than 2 billion COVID-19 doses across the world this year. In an updated forecast published on Thursday, it said it planned to deliver around 1.8 billion doses in 2021 to 92 poorer countries, covering around 27% of their populations.

The scheme - led by the WHO, the GAVI vaccine alliance and the Coalition for Epidemic Preparedness Innovations (CEPI)- was set up last year amid concerns that poorer nations would lose out while rich countries scrambled to procure COVID-19 vaccines to inoculate their populations.

COVAX has so far secured future vaccine suplies from AstraZeneca, working with Oxford University; the Serum Institute of India (SII) as well as with Sanofi and its partner GSK. It also has a memorandum of understanding over deliveries from Johnson & Johnson.

The Pfizer deal would be COVAX's second, after the one with AstraZeneca, that covers a product with regulatory approval in some countries.

The additional commitment by Pfizer comes as frustration grows in European countries over the U.S. drugmaker's unexpected cut in supplies. Pfizer said last week it would reduce deliveries until early February to upgrade production capacity for a later output boost.

The Pfizer and BioNTech COVID-19 vaccine is the only shot so far to have WHO emergency use listing approval.

On Wednesday, Reuters reported that the WHO plans to approve several COVID-19 vaccines from Western and Chinese manufacturers in the coming weeks and months as it aims for rapid rollouts in poorer countries.

BioNTech and Pfizer said this month they were aiming to deliver 2 billion vaccine doses this year, up from a previous goal of 1.3 billion.

Their shot is more complicated to transport and store, requiring ultra-cold freezers, which may not be practical for poorer countries with hot climates. (Reporting by Kate Kelland in London and Ludwig Burger in Frankfurt; Editing by Josephine Mason and Hugh Lawson)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.14% 7005 Delayed Quote.-6.36%
BIONTECH SE -6.14% 90.29 Delayed Quote.18.01%
GLAXOSMITHKLINE PLC 0.74% 1252.2 Delayed Quote.-7.38%
PFIZER INC. -0.12% 34.35 Delayed Quote.-6.68%
SANOFI 1.28% 78.37 Real-time Quote.-1.68%
All news about ASTRAZENECA PLC
04:06pASTRAZENECA  : The latest news on COVID-19 developments in Canada for March 8
AQ
12:29pTHE LATEST : More than 100,000 have died of COVID-19 in Italy
AQ
11:20aWHO says influenza-like illness post COVID-19 vaccinations expected side effe..
RE
10:46aASTRAZENECA  : Berenberg reiterates its Buy rating
MD
10:21aASTRAZENECA  : Germany looks to AstraZeneca shot to boost vaccine rollout
AQ
07:30aASTRAZENECA  : Italy Green-lights AstraZeneca's COVID-19 Vaccine For People Over..
MT
06:35aASTRAZENECA  : Barclays Lifts AstraZeneca PT, Keeps Overweight Rating
MT
06:11aASTRAZENECA  : Indonesia's Bio Farma To Receive 1.1 Million AstraZeneca COVID-19..
MT
05:38aASTRAZENECA  : Barclays gives a Buy rating
MD
05:38aTHE LATEST : Germany ramps up use of AstraZeneca vaccine
AQ
More news
Financials (USD)
Sales 2021 30 875 M - -
Net income 2021 4 710 M - -
Net Debt 2021 11 049 M - -
P/E ratio 2021 19,4x
Yield 2021 4,07%
Capitalization 90 026 M 124 B -
EV / Sales 2021 3,27x
EV / Sales 2022 2,86x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,45 $
Last Close Price 70,05 $
Spread / Highest target 124%
Spread / Average Target 84,8%
Spread / Lowest Target 35,4%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-6.36%124 268
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-3.56%274 753
PFIZER INC.-6.57%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971